- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07937891
The PRECISE-DIET Trial
Precision Nutrition Versus Standard Dietary Care: Effect of Personalised Nutrition Guidance Based on Continuous Glucose Monitoring in Type 2 Diabetes - The PRECISE-DIET Trial
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Zandra Overgaard Pedersen, MSc. Health Science
- Numéro de téléphone: 24456114
- E-mail: zandra.overgaard.pedersen@regionh.dk
Sauvegarde des contacts de l'étude
- Nom: Bettina Ewers, PhD
- Numéro de téléphone: 30912997
- E-mail: bettina.ewers@regionh.dk
Lieux d'étude
-
-
-
Herlev, Danemark, 2730
- Steno Diabetes Center Copenhagen
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- T2D
- Diabetes duration of ≥12 months
- Age ≥18 years
- HbA1c ≥58 mmol/mol
- Attending the SDCC outpatient clinic
- Provided voluntary signed informed consent
Exclusion Criteria:
- Inability to understand the study information
- Medical complications that prevent lowering HbA1c to below 58 mmol/mol
- Use of insulin therapy
- Low daily carbohydrate intake (defined as below 25 E% or 100 g/day) prior to study inclusion
- Systematic use of corticosteroids
- Using or requiring a specialised diet (e.g., protein restriction in kidney disease)
- Circumstances that affect HbA1c (e.g., liver disease and anaemia)
- Known or suspected drug or alcohol abuse
- Pregnancy or breastfeeding or plans of pregnancy within the study period
- Participation in other clinical trials
- Individuals with a BMI of <27 kg/m²
- Initiation of GLP-1 receptor agonist or SGLT inhibitor therapy within the previous 3 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personalised dietary intervention
CGM-supported personalised carbohydrate recommendations |
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes. |
|
Comparateur actif: Standard dietary counselling
Standard dietary counselling for type 2 diabetes |
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in HbA1c
Délai: Baseline to 6 months
|
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months |
Baseline to 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in HbA1c at 12 months
Délai: Baseline to 12 weeks and 12 months
|
Between-group difference in HbA1c change (mmol/mol) |
Baseline to 12 weeks and 12 months
|
|
Time in range (TIR)
Délai: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose 3.9-10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time above range (TAR)
Délai: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose >10.0 mmol/L |
Baseline, 6 and 12 months
|
|
Time below range (TBR)
Délai: Baseline, 6 and 12 months
|
Percentage of CGM time with glucose <3.9 mmol/L |
Baseline, 6 and 12 months
|
|
Estimated HbA1c
Délai: Baseline, 6 and 12 months
|
HbA1c estimated from CGM data (mmol/mol) |
Baseline, 6 and 12 months
|
|
Change in glycaemic variability
Délai: Baseline, 6 and 12 months
|
Coefficient of variation (%) derived from CGM |
Baseline, 6 and 12 months
|
|
Body mass index (BMI)
Délai: Baseline, 6 and 12 months
|
kg/m² |
Baseline, 6 and 12 months
|
|
Waist and hip circumference
Délai: Baseline, 6 and 12 months
|
cm |
Baseline, 6 and 12 months
|
|
Blood pressure
Délai: Baseline, 6 and 12 months
|
Systolic and diastolic (mmHg) |
Baseline, 6 and 12 months
|
|
plasma glucose
Délai: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Plasma insulin
Délai: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
C-peptide
Délai: Baseline, 6 and 12 months
|
pmol/L |
Baseline, 6 and 12 months
|
|
Total cholesterol
Délai: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
LDL cholesterol
Délai: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
HDL cholesterol
Délai: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Triglycerides
Délai: Baseline, 6 and 12 months
|
mmol/L |
Baseline, 6 and 12 months
|
|
Diabetes distress (questionnaire)
Délai: Baseline, 6 and 12 months
|
Problem Areas in Diabetes (PAID) score |
Baseline, 6 and 12 months
|
|
Treatment satisfaction (questionnaire)
Délai: Baseline, 6 and 12 months
|
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score |
Baseline, 6 and 12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in glucose-lowering medication
Délai: Baseline, 6 and 12 months
|
Changes in type and dose of glucose-lowering medication |
Baseline, 6 and 12 months
|
|
Personality traits (questionnaire)
Délai: Baseline
|
Big Five Inventory (BFI-44) scores |
Baseline
|
|
Dietary intake
Délai: Baseline and 6 months
|
Total energy intake and macronutrient composition from a 3-day food record |
Baseline and 6 months
|
|
Physical activity
Délai: Baseline and 6 months
|
Physical activity level measured with an AX3 accelerometer worn for 7 days |
Baseline and 6 months
|
|
Carbohydrate estimation ability (questionnaire)
Délai: Baseline, 6 and 12 months
|
Accuracy of participants' carbohydrate estimates |
Baseline, 6 and 12 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- H-26063596
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .